GILD scores FDA win for HDV drug, CHMP backs Trodelvy
- Posted on May 25, 2026
- By Bing News
- 0 Views
- 1 min read
GILD scores FDA win for HDV drug, CHMP backs Trodelvy
Gilead Sciences, Inc. GILD announced that the FDA has granted accelerated approval to Hepcludex (bulevirtide-gmod) for adults with chronic hepatitis delta virus (HDV) infection. The approval makes Hepcludex the first FDA-approved therapy for HDV in the United States. Shares of GILD inched up 3% on May 22, following the news. Year to date, shares have gained 9.5% against the industry's decline of 0.3%. Image Source: Zacks Investment Research More...
